← Library
Abaloparatide
FDA ApprovedSince 2017
Also known as Tymlos
Function
Primary
Postmenopausal Osteoporosis
Mechanism
PTHrP(1-34) analog — selective PTH1R signaling favoring bone formation over resorption; faster BMD gain than teriparatide.
Evidence
Clinical RCT (Phase III)
Research
Phase III ACTIVE trial
Dosing
Range
80 mcg/day
Frequency
Daily
Route
Subcutaneous
Cycling
Max 2-year lifetime use.
Benefits
- ·Greater BMD gains vs teriparatide
- ·Vertebral and non-vertebral fracture reduction
- ·Daily autoinjector
Risks
- ·Osteosarcoma (class warning)
- ·Hypercalcemia
- ·Dizziness
- ·Palpitations
Contraindications
- ·Prior skeletal radiation
- ·Bone metastases
- ·Pediatric
Regulatory
FDA-Approved Rx
Functional Groups
Cited Works
- Miller PD et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures (ACTIVE). JAMA. 2016;316:722.source